Clinical Trials in Chūō, Yamanashi
15 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled282 locationsNCT06925737
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled253 locationsNCT06717347
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled167 locationsNCT06456346
Recruiting
Phase 1
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled6 locationsNCT07340138
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Arthritis, Rheumatoid
Merck Sharp & Dohme LLC182 enrolled62 locationsNCT07176390
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi10 enrolled11 locationsNCT06791291
Recruiting
Phase 3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Polymyalgia Rheumatica
Novartis Pharmaceuticals288 enrolled115 locationsNCT06331312
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502
Recruiting
Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma
Renal Cell Cancer Metastatic
Zhe Chen145 enrolled1 locationNCT07240610
Recruiting
Phase 1
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
Solid TumorsHepatocellular Carcinoma (HCC)Malignant Melanoma+1 more
Chiome Bioscience Inc.66 enrolled5 locationsNCT06636435
Recruiting
Phase 3
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Myeloproliferative NeoplasmPrimary Myelofibrosis
PharmaEssentia150 enrolled1 locationNCT06468033
Recruiting
Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Esophageal CancerRecurrenceDNA Methylation
City of Hope Medical Center150 enrolled2 locationsNCT06476067
Recruiting
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell CarcinomaChemotherapy EffectDNA Methylation
City of Hope Medical Center150 enrolled1 locationNCT06490003